Core Viewpoint - Decibel Cannabis Company Inc. reported strong financial results for Q2 2025, showcasing significant growth in both domestic and international markets, driven by the integration of AgMedica and successful marketing initiatives [2][6]. Financial Performance - Gross Canadian recreational sales reached CAD 38.2 million in Q2 2025, up from CAD 33.6 million in Q2 2024, marking a 14.5% increase [5]. - Net Canadian recreational sales were CAD 23.7 million, a 7% increase year-over-year [6]. - International sales surged to CAD 6.1 million, a significant increase from CAD 37, representing a 16,500% year-over-year growth [5][6]. - Total gross revenue for Q2 2025 was CAD 44.4 million, compared to CAD 33.7 million in Q2 2024, reflecting a 32% increase [5]. - Net revenue for the quarter was CAD 29.8 million, a 35% increase compared to CAD 22.2 million in Q2 2024 [6]. Profitability Metrics - Gross profit before fair value adjustments was CAD 14.0 million, with a gross margin of 47%, up from 42% in Q2 2024 [5][6]. - Adjusted EBITDA for Q2 2025 was CAD 6.3 million, a 60% increase year-over-year [6]. - Free cash flow improved to CAD 2.2 million, a year-over-year increase of CAD 4.3 million [6]. Strategic Developments - The successful integration of AgMedica has established a robust international platform for Decibel, enhancing its global market presence [2]. - The company anticipates strong international demand and plans to expand its contracts and volumes in the second half of 2025 [6]. Operational Highlights - Decibel operates three cultivation facilities and a processing center, positioning itself as a leader in high-quality cannabis products [11]. - The company has executed additional contracts for cannabis exports, with expectations for increased volumes in future periods [6].